MDD
Pipeline by Development Stage
Drug Modality Breakdown
On Market (1)
Approved therapies currently available
Competitive Landscape
6 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Clinical Trials (6)
Total enrollment: 8,446 patients across 6 trials
Vortioxetine in Patients With Depression Coexisting With General Anxiety Disorder (GAD)
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD
Resonant Frequency rTMS: A Novel Approach to Target Circuit Modulation in Major Depressive Disorder
A Retrospective Study to Evaluate NeuroStar® Advanced Therapy in Adolescents
The MOOD Study - External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for the Treatment of Major Depressive Disorder (MDD)
Related Jobs
Director, Human Resources
Director/Senior Director, CMC, Drug Substance
Behavioral Health Technician (Greenbrook)
Specialist, Quality Assurance
Regional Business Director, Symbravo (Southeast Region)
Regional Business Director, Symbravo (Southwest Region)
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.